Neurodegenerative Diseases: The Distorted Origami of Protein Misfolding Neil R. Cashman MD Professor and Canada Research Chair Brain Research Centre Department.

Slides:



Advertisements
Similar presentations
The Aging Brain The brain changes with age The frontal cortex & hippocampus are critical to learning, memory, planning and other cognitive activities,
Advertisements

AD Research Update Steven H. Ferris, PhD Friedman Professor and Director NYU Alzheimer’s Disease Center Silberstein Alzheimer’s Institute Center for Cognitive.
MECHANISMS OF AGING TheoryPrinciples DNA & Genetic Theory Aging is predetermined by genetic programming. Neuroendocrine Theory Loss of hypothalamic regulation.
The following is an animation demonstrating the effects of prions on neuronal cells. Prions are misfolded proteins which provoke an array of neurodegenerative.
Disorders caused by pathological conformation of proteins
1986 Elected Fellow, Royal Society of Canada 2010 Elected Fellow, Canadian Academy of Health Sciences Speakers list Speakers from Canada Anthony George.
A view into Neurodegeneration and neurodegenerative diseases Bahareh Eftekharzadeh Laboratory of Dr. Xavier Salvatella SemesterI Crazy about Biomedicine.
Amphotericin B Two-edged sword or Swiss army knife? Bridging the gap between Alzheimer’s and Prion diseases.
Simoa Accelerator Laboratory
Chapter 21. Molecular Mechanisms of Neurological Disease Copyright © 2014 Elsevier Inc. All rights reserved.
Dr Stewart Hay, CEO | | (03) www.therapeuticinnovation.com.au.
3D Bioprinting
PEPTIMMUNE CONFIDENTIAL IMMUNOMODULATORY THERAPY FOR PARKINSON’S DISEASE Induction of an anti-inflammatory immune response toward toxic species of alpha-synuclein.
Holly Allen CREUTZFELDT-JAKOB DISEASE.  Human equivalent of mad cow disease  Rare, degenerative, fatal disease  Approximately 1 case per million per.
Protein Misfolding: Therapeutic Implications
Roderic G. Eckenhoff, MD Dept. Anesthesiology & Critical Care, University of Pennsylvania Hypothesis: Inhaled anesthetics.
Diseases Learning Targets and Success Criteria. Infection Learning Target I can explain how viruses, bacteria, fungi and parasites may infect the human.
Pronucleon TM Amplified Misfolded Protein Diagnostic Assay (AMP-D) Kenton L. Lohman, Ph.D. VP Assay Development Adlyfe Inc., Rockville, MD.
A carboxylated Zn-phthalocyanine inhibits the fibril formation of Alzheimer’s amyloid β peptide Atsushi Nagai Dept. Laboratory Medicine Shimane University.
Enzyme-Linked Immunosorbent Assay [ELISA] BCH 462[practical] Lab#5.
Α-synuclein, Lewy Bodies, Prions, and Parkinson’s Disease Cody McCullough & Sara Homsi BCM 465 April 19 th, 2010.
By : Amirah nu’aimi Sharifah Nurul Hanim TASK 2 – DISCUSS THE EXAMPLE OF PROTEIN FOLDING DISEASE BY STATING THE MECHANISM.
The Worldwide Epidemic of Senile Dementias- Challenges of Pre-Clinical Treatment Evolving Diagnostic Approaches Dimitrios Kapogiannis AAAS 2015 Annual.
PATHOLOGIC AGGREGATION OF THE BRAIN PROTEIN  -SYNUCLEIN CAUSES CELL DEATH IN PARKINSON AND ALZHEIMER DISEASE, Wenbo Zhou, PhD and Curt R. Freed, MD Division.
1 HPerron TSEAC Detection of PrP res in plasma H. Perron Presented by P van Driessche.
Diagnostics Alan S. Rudolph PhD MBA Chief Executive Officer Adlyfe Inc. Rockville, MD Innovation is in our blood Diagnostics.
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver” Elizabeth J. Phillips, MD, FRCPC,FRACP, FACTM Professor & Director, Centre for Clinical.
Advances in polyglutamine disease research & therapy
This is the Age of Biotechnology According to the U.S. Bureau of Labor Statistics, employment of biological scientists is projected to grow 21 percent.
The Purification and Characterization
Protection of rat primary hippocampal cultures from Aβ cytotoxicity by pro-inflammatory molecules is mediated by astrocytes Neurobiology of disease, Vol.
Proteins as Pathogens Stanley B. Prusiner, MD The Nobel Prize in Physiology or Medicine Presented by Shannon S. Rickner-Schmidt.
How are medicines developed?. What is it? What’s inside?
Introduction Results Conclusions Acknowledgements Alzheimer’s Disease (AD) is the most common chronic degenerative neurological disease, and there are.
Mounting Evidence that Endocytosis Regulates  -Synuclein Degradation Jaime Pérez Pineda Advanced Cell Biology Fall 2009.
Treatment of Protein Misfolding Diseases with Novel Biologics
Protein conformational disorders Amyloid Alice Skoumalová.
The Seprion Separation System Development of a feasible blood screening protocol for abnormal prion protein Stuart Wilson Microsens Biotechnologies.
Dennis Bourdette, MD VA MS Center of Excellence-West and
Bioinformatics: Practical Application of Simulation and Data Mining Protein Aggregation I Prof. Corey O’Hern Department of Mechanical Engineering & Materials.
Removal of Infectious Prions from Red Cell Concentrates Blood Safety Advisory Committee March 17, 2005 Joseph Cervia, M.D., FACP,FAAP Professor of Clinical.
Recent advances in Trace Element Research in Health and Disease Dubrovnik, Oct 2015 Mirjana Babić Leko, mag.biol.mol Department of Neuroscience Croatian.
Under the supervision of miklós jászberényi
High resolution MRI at 21.1 T of the hippocampus and temporal lobe white matter in the differential classification of Alzheimer’s Disease & Diffuse Lewy.
Introduction HYPOTHESIS A popular membrane-active antifungal agent, Amphotericin B (AmB) and its derivatives have been shown to be among the very few agents.
A NTIBODY -B ASED T HERAPEUTICS FOR T REATING A LZHEIMER ’ S AND P ARKINSON ’ S D ISEASES Taylor Brownlee Dr. Michael Sierks Chemical Engineering 2012.
A novel therapy and companion biomarker for Alzheimer’s disease.
Applications of Nanotechnology in Alzheimer’s Disease BioE 494 – Atomic and Molecular Nanotechnology Fall 2007 Deivya Bansal.
Airborne particulate pollution as a potential environmental risk factor for Alzheimer's disease Professor David Allsop, Faculty of Health and Medicine,
Treating Chronic and Acute Neurodegeneration by Inhibiting Neurotoxic Aggregating Proteins AP/PD Conference April 2, 2017.
CLINICAL CORRELATIONS
Imaging Techniques Used to Study Biological Systems
Protein conformational disorders
Protein conformational disorders
Neurodegeneration caused by prions. A
What will it take to develop an effective Alzheimer’s drug?
Q: How can we prevent or treat Alzheimer’s Disease?
Immunotherapeutic Approaches for Alzheimer’s Disease
Figure 2 ER stress and proteostasis in neurodegenerative diseases
RESEARCH & INNOVATION SHOWCASE Dr Jill Madine
Protein Misfolding, Amyloid Formation, and Neurodegeneration
Pathways to Primary Neurodegenerative Disease
Volume 5, Issue 3, Pages (November 2013)
Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”
Dominic M. Walsh, Dennis J. Selkoe  Neuron 
Amyloid-beta circulates in blood and brain
Mechanisms Underlying Inflammation in Neurodegeneration
Figure 3 Blood–brain barrier breakdown promotes neurodegeneration
Key chaperome modifier activities in misfolding-disease progression.
-supported study By Dr. Chao Peng
Presentation transcript:

Neurodegenerative Diseases: The Distorted Origami of Protein Misfolding Neil R. Cashman MD Professor and Canada Research Chair Brain Research Centre Department of Medicine (Neurology) University of British Columbia Academic Director, ALS Centre GF Strong Hospital

Caprion Pharmaceuticals Founder and Scientific Advisor (YYR PrP Sc Epitope) Amorfix Life Sciences Founder and CSO, Chair BoD (Epitope Protection, SOD1 Epitopes, ProMIS) Biogen-Idec Corporation (SOD1 DSE Immunotherapy) Cangene Corporation (Aβ Oligomer Epitope) Prothena Biosciences (Scientific Advisory Board) Industrial Engagement

Cancer Neurodegeneration Cancer Neurodegeneration Disruptive Idea 1: Protein Misfolding and Disease

Disruptive Idea 2: Antibodies Can Selectively Target Misfolded Proteins while Sparing Native Isoforms Efficacy: Specific targeting of a pathogenic species – Neutralization of toxicity – Blockade of propagation – Acceleration of degradation – Minimal “target distraction” Safety: Selective sparing of normal proteins – Preservation of normal function – Minimization of autoimmunity – Minimal regimens in therapeutic vaccines

5 Amorfix Aggregated Aβ Assay (A 4 ): Test Overview Part 1: Aβ Aggregate Isolation Part 2: Aβ Quantification Disaggregated Aβ Magnetic bead coupled to 1F8/2H12 Europium bead coupled to 4G10 Aβ Ultra-Sensitive Immunoassay AMFIA™ Quantifies Aβ in its monomeric form Immunoassay sensitivity Aβ-Disaggregation ELUATE (aggregated Aβ) FLOW (monomeric Aβ) A 4 Matrix Capture and concentrate Aβ aggregates INPUT Sample/homogenate preparation Brain, plasma, CSF, cell culture

Propagated Protein Misfolding Diseases ALS (aggregates) Parkinson’s diseases (Lewy Bodies) Alzheimer’s diseases (plaques and tangles) Prion diseases (PrP amyloid plaques) Huntington’s disease (aggregates) TTR amyloid neuropathy (plaques) Schizophrenia (aggregates) Type 2 diabetes (aggregates)

Acknowledgements University of Toronto Chakrabartty group Pai group Prosser group U Sask – VIDO, PREVENT Napper group CIHR: III, IA, INMHA ALS Canada PrioNet Canada Canada Research Chairs CFI & BCKDF Cangene/Emergent Corp UBC Cashman group Plotkin group Mackenzie group Jia group Marziali group Wang group Wellington group University of Alberta Wishart group Kovalenko group Amorfix Life Sciences

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.